{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:48:12Z","timestamp":1768438092711,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T00:00:00Z","timestamp":1354147200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) is the most common type of neuroendocrine tumors accounting for 65\u201375% of neuroendocrine neoplasms (NENs). Given the fact that there are few studies on GEP-NENs among Chinese patients, we performed a retrospective study in South China.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Totally 178 patients with GEP-NENs treated at the First Affiliated Hospital of Sun Yat-sen University between January 1995 and May 2012 were analyzed retrospectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Pancreas was found the most common site of involvement (34.8%). 149 patients (83.7%) presented as non-functional tumors with non-specific symptoms such as abdominal pain (33.7%); carcinoid syndrome was not found in this study. Several methods are useful for localization of GEP-NENs, yielding varied detection rates from 77.8% to 98.7%. Positive rates of chromogranin A (CgA) and synaptophysin (Syn) immunhistochemically were 69.1% and 90.2%, respectively. 87 patients (51.5%) had G1 tumors, 31(18.3%) G2 tumors and 51 (30.2%) G3 tumors. Neuroendocrine tumor (NET), neuroendocrine carcinoma (NEC) and mixed adenoendocrine carcinoma (MANEC) were 69.8%, 27.2% and 3.0%, respectively. 28.1% of patients presented with distant disease. Surgery was performed in 152 (85.4%) patients, and overall 5-year survival rate was 54.5%. Functionality, G1 grading and NET classification were associated with favorable prognosis in univariate analysis. Distant metastasis contributed to unfavorable prognosis of these tumors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Nonfunctional tumors with non-specific symptoms account for the majority of GEP-NENs. Diagnosis depends on pathological classification. Multidisciplinary treatments could help improve the outcome.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1472-6823-12-30","type":"journal-article","created":{"date-parts":[[2012,11,30]],"date-time":"2012-11-30T01:15:07Z","timestamp":1354238107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995\u20132012) in South China"],"prefix":"10.1186","volume":"12","author":[{"given":"Yu-hong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-hu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,29]]},"reference":[{"issue":"1","key":"147_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","volume":"9","author":"IM Modlin","year":"2008","unstructured":"Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008, 9 (1): 61-72. 10.1016\/S1470-2045(07)70410-2.","journal-title":"Lancet Oncol"},{"issue":"4","key":"147_CR2","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/cncr.11105","volume":"97","author":"IM Modlin","year":"2003","unstructured":"Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003, 97 (4): 934-959. 10.1002\/cncr.11105.","journal-title":"Cancer"},{"issue":"18","key":"147_CR3","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A: One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008, 26 (18): 3063-3072. 10.1200\/JCO.2007.15.4377.","journal-title":"J Clin Oncol"},{"key":"147_CR4","volume-title":"WHO classification of tumours of the digestive system","author":"FT Bosman","year":"2010","unstructured":"Bosman FT, Carneiro F, Hruban RH, Theise ND: WHO classification of tumours of the digestive system. 2010, Lyon: International Agency for Research on Cancer, 4","edition":"4"},{"issue":"4","key":"147_CR5","first-page":"257","volume":"40","author":"Chinese Pathologic Consensus Group for Gastrointestinal and Pancreatic Neuroendocrine Neoplasm","year":"2011","unstructured":"Chinese Pathologic Consensus Group for Gastrointestinal and Pancreatic Neuroendocrine Neoplasm: China Consensus Guidelines for the standards of histopathologic diagnosis in Gastroenteropancreatic Neuroendocrine neoplasm. Chin J Pathol. 2011, 40 (4): 257-262.","journal-title":"Chin J Pathol"},{"issue":"10","key":"147_CR6","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1002\/cncr.23883","volume":"113","author":"O Hauso","year":"2008","unstructured":"Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, Modlin IM: Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008, 113 (10): 2655-2664. 10.1002\/cncr.23883.","journal-title":"Cancer"},{"issue":"9","key":"147_CR7","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1093\/annonc\/mdq022","volume":"21","author":"R Garcia-Carbonero","year":"2010","unstructured":"Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez Del Prado MP, Alonso Orduna V, Sevilla-Garcia I, Villabona-Artero C, Beguiristain-Gomez A, Llanos-Munoz M: Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010, 21 (9): 1794-1803. 10.1093\/annonc\/mdq022.","journal-title":"Ann Oncol"},{"issue":"4","key":"147_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1159\/000242109","volume":"90","author":"U Ploeckinger","year":"2009","unstructured":"Ploeckinger U, Kloeppel G, Wiedenmann B, Lohmann R: The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology. 2009, 90 (4): 349-363. 10.1159\/000242109.","journal-title":"Neuroendocrinology"},{"issue":"3","key":"147_CR9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1053\/j.gastro.2007.01.006","volume":"132","author":"C Lepage","year":"2007","unstructured":"Lepage C, Rachet B, Coleman MP: Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterology. 2007, 132 (3): 899-904. 10.1053\/j.gastro.2007.01.006.","journal-title":"Gastroenterology"},{"issue":"3","key":"147_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1743-7563.2011.01423.x","volume":"7","author":"T Lim","year":"2011","unstructured":"Lim T, Lee J, Kim JJ, Lee JK, Lee KT, Kim YH, Kim KW, Kim S, Sohn TS, Choi DW: Gastroenteropancreatic neuroendocrine tumors: incidence and treatment outcome in a single institution in Korea. Asia Pac J Clin Oncol. 2011, 7 (3): 293-299. 10.1111\/j.1743-7563.2011.01423.x.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"2","key":"147_CR11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/cncr.23159","volume":"112","author":"AF Li","year":"2008","unstructured":"Li AF, Hsu CY, Li A, Tai LC, Liang WY, Li WY, Tsay SH, Chen JY: A 35-year retrospective study of carcinoid tumors in Taiwan: differences in distribution with a high probability of associated second primary malignancies. Cancer. 2008, 112 (2): 274-283. 10.1002\/cncr.23159.","journal-title":"Cancer"},{"issue":"6","key":"147_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/gut.2006.109157","volume":"56","author":"T Konishi","year":"2007","unstructured":"Konishi T, Watanabe T, Kishimoto J, Kotake K, Muto T, Nagawa H: Prognosis and risk factors of metastasis in colorectal carcinoids: results of a nationwide registry over 15 years. Gut. 2007, 56 (6): 863-868. 10.1136\/gut.2006.109157.","journal-title":"Gut"},{"issue":"6","key":"147_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00535-007-2056-6","volume":"42","author":"T Ito","year":"2007","unstructured":"Ito T, Tanaka M, Sasano H, Osamura YR, Sasaki I, Kimura W, Takano K, Obara T, Ishibashi M, Nakao K: Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol. 2007, 42 (6): 497-500. 10.1007\/s00535-007-2056-6.","journal-title":"J Gastroenterol"},{"issue":"4","key":"147_CR14","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s13277-011-0170-9","volume":"32","author":"DS Wang","year":"2011","unstructured":"Wang DS, Zhang DS, Qiu MZ, Wang ZQ, Luo HY, Wang FH, Li YH, Xu RH: Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas. Tumour Biol. 2011, 32 (4): 697-705. 10.1007\/s13277-011-0170-9.","journal-title":"Tumour Biol"},{"issue":"1","key":"147_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/01.sla.0000129342.67174.67","volume":"240","author":"MA Maggard","year":"2004","unstructured":"Maggard MA, O\u2019Connell JB, Ko CY: Updated population-based review of carcinoid tumors. Ann Surg. 2004, 240 (1): 117-122. 10.1097\/01.sla.0000129342.67174.67.","journal-title":"Ann Surg"},{"issue":"4","key":"147_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00268-003-7019-3","volume":"28","author":"JJ Van Gompel","year":"2004","unstructured":"Van Gompel JJ, Sippel RS, Warner TF, Chen H: Gastrointestinal carcinoid tumors: factors that predict outcome. World J Surg. 2004, 28 (4): 387-392. 10.1007\/s00268-003-7019-3.","journal-title":"World J Surg"},{"issue":"4","key":"147_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/00000658-200010000-00010","volume":"232","author":"MW Onaitis","year":"2000","unstructured":"Onaitis MW, Kirshbom PM, Hayward TZ, Quayle FJ, Feldman JM, Seigler HF, Tyler DS: Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg. 2000, 232 (4): 549-556. 10.1097\/00000658-200010000-00010.","journal-title":"Ann Surg"},{"issue":"3","key":"147_CR18","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/PAS.0b013e3181ce1447","volume":"34","author":"DS Klimstra","year":"2010","unstructured":"Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gonen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV: Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010, 34 (3): 300-313. 10.1097\/PAS.0b013e3181ce1447.","journal-title":"Am J Surg Pathol"},{"key":"147_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1196\/annals.1294.025","volume":"1014","author":"UF Pape","year":"2004","unstructured":"Pape UF, Bohmig M, Berndt U, Tiling N, Wiedenmann B, Plockinger U: Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center. Ann N Y Acad Sci. 2004, 1014: 222-233. 10.1196\/annals.1294.025.","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"147_CR20","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/00000658-199906000-00008","volume":"229","author":"KO Shebani","year":"1999","unstructured":"Shebani KO, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK, Ott MJ: Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg. 1999, 229 (6): 815-821. 10.1097\/00000658-199906000-00008. discussion 822\u2013813.","journal-title":"Ann Surg"},{"issue":"3","key":"147_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3109\/02841868909111212","volume":"28","author":"AI Vinik","year":"1989","unstructured":"Vinik AI, Thompson N, Eckhauser F, Moattari AR: Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management. Acta Oncol. 1989, 28 (3): 389-402. 10.3109\/02841868909111212.","journal-title":"Acta Oncol"},{"issue":"9","key":"147_CR22","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1111\/j.1572-0241.2000.02480.x","volume":"95","author":"MA Anderson","year":"2000","unstructured":"Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM: Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000, 95 (9): 2271-2277. 10.1111\/j.1572-0241.2000.02480.x.","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"147_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000051855","volume":"62","author":"T Zimmer","year":"2000","unstructured":"Zimmer T, Scherubl H, Faiss S, Stolzel U, Riecken EO, Wiedenmann B: Endoscopic ultrasonography of neuroendocrine tumours. Digestion. 2000, 62 (Suppl 1): 45-50.","journal-title":"Digestion"},{"issue":"11","key":"147_CR24","doi-asserted-by":"publisher","first-page":"828","DOI":"10.4321\/S1130-01082006001100004","volume":"98","author":"MJ Varas Lorenzo","year":"2006","unstructured":"Varas Lorenzo MJ, Miquel Collell JM, Maluenda Colomer MD, Boix Valverde J, Armengol Miro JR: Preoperative detection of gastrointestinal neuroendocrine tumors using endoscopic ultrasonography. Rev Esp Enferm Dig. 2006, 98 (11): 828-883.","journal-title":"Rev Esp Enferm Dig"},{"issue":"18","key":"147_CR25","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/jnci\/djn275","volume":"100","author":"IM Modlin","year":"2008","unstructured":"Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E: Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008, 100 (18): 1282-1289. 10.1093\/jnci\/djn275.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"147_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000182196","volume":"90","author":"G Kloppel","year":"2009","unstructured":"Kloppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, Scarpa A, Scoazec JY, Wiedenmann B, Papotti M: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009, 90 (2): 162-166. 10.1159\/000182196.","journal-title":"Neuroendocrinology"},{"issue":"5","key":"147_CR27","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/1097-0142(19940301)73:5<1505::AID-CNCR2820730530>3.0.CO;2-V","volume":"73","author":"RM Bukowski","year":"1994","unstructured":"Bukowski RM, Tangen CM, Peterson RF, Taylor SA, Rinehart JJ, Eyre HJ, Rivkin SE, Fleming TR, Macdonald JS: Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer. 1994, 73 (5): 1505-1508. 10.1002\/1097-0142(19940301)73:5<1505::AID-CNCR2820730530>3.0.CO;2-V.","journal-title":"Cancer"},{"issue":"8","key":"147_CR28","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/1097-0142(20010415)91:8<1543::AID-CNCR1163>3.0.CO;2-N","volume":"91","author":"SM Ansell","year":"2001","unstructured":"Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J: A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer. 2001, 91 (8): 1543-1548. 10.1002\/1097-0142(20010415)91:8<1543::AID-CNCR1163>3.0.CO;2-N.","journal-title":"Cancer"},{"issue":"22","key":"147_CR29","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1200\/JCO.2005.03.616","volume":"23","author":"W Sun","year":"2005","unstructured":"Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG: Phase II\/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005, 23 (22): 4897-4904. 10.1200\/JCO.2005.03.616.","journal-title":"J Clin Oncol"},{"issue":"21","key":"147_CR30","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","volume":"303","author":"CG Moertel","year":"1980","unstructured":"Moertel CG, Hanley JA, Johnson LA: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980, 303 (21): 1189-1194. 10.1056\/NEJM198011203032101.","journal-title":"N Engl J Med"},{"issue":"8","key":"147_CR31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1056\/NEJM199202203260804","volume":"326","author":"CG Moertel","year":"1992","unstructured":"Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992, 326 (8): 519-523. 10.1056\/NEJM199202203260804.","journal-title":"N Engl J Med"},{"issue":"2","key":"147_CR32","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/cncr.25425","volume":"117","author":"JR Strosberg","year":"2011","unstructured":"Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011, 117 (2): 268-275. 10.1002\/cncr.25425.","journal-title":"Cancer"},{"issue":"2","key":"147_CR33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","volume":"68","author":"CG Moertel","year":"1991","unstructured":"Moertel CG, Kvols LK, O\u2019Connell MJ, Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991, 68 (2): 227-232. 10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I.","journal-title":"Cancer"},{"issue":"22","key":"147_CR34","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1200\/JCO.2005.05.0575","volume":"24","author":"JD Hainsworth","year":"2006","unstructured":"Hainsworth JD, Spigel DR, Litchy S, Greco FA: Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol. 2006, 24 (22): 3548-3554. 10.1200\/JCO.2005.05.0575.","journal-title":"J Clin Oncol"},{"issue":"5","key":"147_CR35","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V","volume":"92","author":"ML Fjallskog","year":"2001","unstructured":"Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK: Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer. 2001, 92 (5): 1101-1107. 10.1002\/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V.","journal-title":"Cancer"},{"issue":"8","key":"147_CR36","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","volume":"81","author":"E Mitry","year":"1999","unstructured":"Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999, 81 (8): 1351-1355. 10.1038\/sj.bjc.6690325.","journal-title":"Br J Cancer"},{"issue":"23","key":"147_CR37","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","volume":"22","author":"MA Kouvaraki","year":"2004","unstructured":"Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004, 22 (23): 4762-4771. 10.1200\/JCO.2004.04.024.","journal-title":"J Clin Oncol"},{"issue":"26","key":"147_CR38","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A: Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008, 26 (26): 4311-4318. 10.1200\/JCO.2008.16.7858.","journal-title":"J Clin Oncol"},{"issue":"20","key":"147_CR39","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","volume":"26","author":"MH Kulke","year":"2008","unstructured":"Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008, 26 (20): 3403-3410. 10.1200\/JCO.2007.15.9020.","journal-title":"J Clin Oncol"},{"issue":"28","key":"147_CR40","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009, 27 (28): 4656-4663. 10.1200\/JCO.2009.22.8510.","journal-title":"J Clin Oncol"},{"issue":"1","key":"147_CR41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","volume":"28","author":"JC Yao","year":"2010","unstructured":"Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010, 28 (1): 69-76. 10.1200\/JCO.2009.24.2669.","journal-title":"J Clin Oncol"},{"issue":"6","key":"147_CR42","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011, 364 (6): 514-523. 10.1056\/NEJMoa1009290.","journal-title":"N Engl J Med"},{"issue":"6","key":"147_CR43","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011, 364 (6): 501-513. 10.1056\/NEJMoa1003825.","journal-title":"N Engl J Med"},{"issue":"6","key":"147_CR44","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/annonc\/mdh216","volume":"15","author":"K Oberg","year":"2004","unstructured":"Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004, 15 (6): 966-973. 10.1093\/annonc\/mdh216.","journal-title":"Ann Oncol"},{"issue":"8","key":"147_CR45","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/0024-3205(87)90690-4","volume":"41","author":"T Karashima","year":"1987","unstructured":"Karashima T, Cai RZ, Schally AV: Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release. Life Sci. 1987, 41 (8): 1011-1019. 10.1016\/0024-3205(87)90690-4.","journal-title":"Life Sci"},{"issue":"Suppl 1","key":"147_CR46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000080743","volume":"80","author":"K Oberg","year":"2004","unstructured":"Oberg K: Future aspects of somatostatin-receptor-mediated therapy. Neuroendocrinology. 2004, 80 (Suppl 1): 57-61.","journal-title":"Neuroendocrinology"},{"issue":"5","key":"147_CR47","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1159\/000007693","volume":"60","author":"S Faiss","year":"1999","unstructured":"Faiss S, Rath U, Mansmann U, Caird D, Clemens N, Riecken EO, Wiedenmann B: Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion. 1999, 60 (5): 469-476. 10.1159\/000007693.","journal-title":"Digestion"},{"issue":"1","key":"147_CR48","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1530\/eje.0.1510107","volume":"151","author":"SV Welin","year":"2004","unstructured":"Welin SV, Janson ET, Sundin A, Stridsberg M, Lavenius E, Granberg D, Skogseid B, Oberg KE, Eriksson BK: High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol\/European Federation of Endocrine Societies. 2004, 151 (1): 107-112. 10.1530\/eje.0.1510107.","journal-title":"Eur J Endocrinol\/European Federation of Endocrine Societies"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6823-12-30.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6823-12-30\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6823-12-30","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6823-12-30.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T20:55:12Z","timestamp":1630529712000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/1472-6823-12-30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,29]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["147"],"URL":"https:\/\/doi.org\/10.1186\/1472-6823-12-30","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,29]]},"assertion":[{"value":"6 August 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"30"}}